<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Pharmakeus on Medium]]></title>
        <description><![CDATA[Stories by Pharmakeus on Medium]]></description>
        <link>https://medium.com/@pharmakeus?source=rss-f3ca80fee88c------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*9kFk0ntoRPZ9Zvc4tCBrvA.jpeg</url>
            <title>Stories by Pharmakeus on Medium</title>
            <link>https://medium.com/@pharmakeus?source=rss-f3ca80fee88c------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Mon, 16 Nov 2026 21:57:23 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@pharmakeus/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[The Relationship between Alcohol Consumption and Cortisol Secretion in an Aging Cohort]]></title>
            <link>https://pharmakeus.medium.com/the-relationship-between-alcohol-consumption-and-cortisol-secretion-in-an-aging-cohort-89f12350485f?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/89f12350485f</guid>
            <category><![CDATA[cortisol]]></category>
            <category><![CDATA[endocrinology]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[alcohol]]></category>
            <category><![CDATA[pharmacology]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Sat, 07 Nov 2020 19:31:22 GMT</pubDate>
            <atom:updated>2020-11-07T19:31:22.948Z</atom:updated>
            <content:encoded><![CDATA[<h3>Abstract</h3><p><strong>Context:</strong> Evidence for an association between alcohol consumption and activity of the hypothalamic-pituitary-adrenal (HPA) axis is inconclusive.</p><p><strong>Objective:</strong> Our objective was to assess the relationship between indices of alcohol consumption and salivary cortisol concentration.</p><p><strong>Design:</strong> This was a cross-sectional study of alcohol consumption and cortisol secretion from phase 7 (2002–2004) of the Whitehall II study.</p><p><strong>Setting:</strong> An occupational cohort originally recruited in 1985–1987 was included in the study.</p><p><strong>Participants:</strong> A total of 2693 men and 977 women had information on cortisol levels and alcohol consumption.</p><p><strong>Outcome Measures:</strong> Saliva samples were taken on waking, waking + 0.5, 2.5, 8, and 12 h, and bedtime for the assessment of cortisol.</p><p><strong>Results:</strong> In men there was a positive association between cortisol and units of alcohol intake per week (3% increase in cortisol per unit of alcohol consumed; <em>P</em> = 0.010). The slope of cortisol decline over the day in heavy drinkers was reduced (heavy drinkers β = −0.155, moderate drinkers β = −0.151), indicating reduced control of the HPA axis in heavy drinkers. In women the cortisol awakening response was greater in heavy drinkers 14.15 nmol/liter (9.12–19.17) compared with moderate drinkers 8.69 nmol/liter (7.72–9.67) (<em>P</em> = 0.037).</p><p><strong>Conclusions:</strong> This study suggests that alcohol consumption is associated with activation of the HPA axis. These results are not due to alcohol consumption on the day, suggesting chronic changes of the HPA axis in heavy drinking groups.</p><p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266962/">NCBI - WWW Error Blocked Diagnostic</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=89f12350485f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[COVID-19 — Pharmacological Interventions]]></title>
            <link>https://pharmakeus.medium.com/covid-19-pharmacological-interventions-93023f7324f9?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/93023f7324f9</guid>
            <category><![CDATA[drugs]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[pharmacology]]></category>
            <category><![CDATA[antivirals]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Wed, 01 Apr 2020 20:39:29 GMT</pubDate>
            <atom:updated>2020-04-04T02:29:52.190Z</atom:updated>
            <content:encoded><![CDATA[<h3>COVID-19 — Pharmacological Interventions for Coronavirus</h3><p><em>Updated 3/31/2020.</em></p><p>The outbreak of COVID-19 has taken a toll on healthcare systems across the world. The goal of this article is to briefly look at pharmacological treatments for this disease — whether clinical or experimental.</p><p>Firstly, let’s consider a shortlist that was compiled by China earlier in March, 2020. The potential treatments from the <em>Handbook of COVID-19 Prevention and Treatment — </em>compiled by clinical experience by the Zhejiang University School of Medicine<em> </em>(full text can be found <a href="https://www.alibabacloud.com/universal-service/pdf_reader?spm=a3c0i.14138300.8102420620.dreadnow.6df3647f2DplbQ&amp;cdnorigin=video-intl&amp;pdf=Read%20Online-Handbook%20of%20COVID-19%20Prevention%20and%20Treatment.pdf">here</a>):</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/609/1*SSklO118fEaNAF3PPzckWw.png" /><figcaption>Drugs commonly used in China during late 2019 and early 2020 clinical applications for COVID-19.</figcaption></figure><p>And see the following sheet for some contradictions that were noted in clinical treatment in China:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/673/1*mXMGiMEwlHKGS00qx-9kBg.png" /><figcaption>Contraindications for each of the treatments note that azithromycin can cause Q-T internal prolongations which can cause cardiac complications.</figcaption></figure><p>Starting with this list we can begin to expand:</p><h4>1. Hydroxychloroquine (<a href="https://www.drugbank.ca/drugs/DB01611">drugbank link</a>):</h4><ul><li>A drug invented during WWII initially used as an anti-malarial it has a long list of off-label uses in history. It is also used in rheumatoid arthritis, lupus erythematosus and other conditions today. Exact mechanisms are not known but is known to affect pH levels in various intracellular components including the vacuoles of malarial parasite cells. It notably affects ACE2 in SARS-CoV-2 and COVID-19. (<a href="https://science.sciencemag.org/content/367/6485/1444/tab-e-letters">Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</a>). This is one of the proposed mechanisms of action that is supposed to be useful for treatment of coronaviruses.</li><li>In terms of clinical effects, it is often cited to be used with azithromycin despite the aforementioned Chinese contraindications of prolonged Q-T levels. One French study showed efficacy with a group of roughly 80 patients in combination with azithro. This may be an effective treatment for patients without any cardiac preconditions.</li><li>Otherwise, it has seen some efficacy in small studies despite contraindications. See studies below:</li></ul><ul><li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32205204">Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.</a></li><li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32196083">COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.</a></li><li><a href="https://www.ncbi.nlm.nih.gov/pubmed/32194152">Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine.</a></li><li><a href="https://www.sciencedirect.com/science/article/pii/S0924857920300996">Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</a></li><li><a href="https://www.sciencedirect.com/science/article/pii/S0924857920300820">Chloroquine and hydroxychloroquine as available weapons to fight COVID-19</a></li></ul><h4>2. <a href="https://www.drugbank.ca/drugs/DB01601">Lopinavir </a>/ <a href="https://www.drugbank.ca/drugs/DB00503">Ritonavir</a> (drugbank links for each respectively):</h4><ul><li>This is a combination drug given as an HIV protease inhibitor for patients to manage HIV long-term. These drugs inhibit the protease enzyme that allow HIV-1 form new replicating proteins for the virus. However, Ritonavir is a potent inhibitor of cytochrome P450 CYP3A4 and thus can have a large variety of contraindications. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2001282">This study</a> mentioned that no benefit was observed with lopinavir-ritonavir treatment in 99 patients.</li></ul><p><a href="https://www.sciencedirect.com/science/article/pii/S1201971220301326">Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression</a></p><h4>3. Umifenovir (or as referenced as <a href="https://www.drugbank.ca/drugs/DB13609">Arbidol</a>):</h4><ul><li>Arbidol is a drug only approved for use in Russia and China as a direct-acting antiviral. It is considered to have a broad spectrum of effects on both RNA and DNA viruses and their replication processes throughout. <strong>This drug is likely totally unavailable in the US and much of Europe.</strong></li></ul><h4>4. Imipenem (<a href="https://www.drugbank.ca/drugs/DB01598">drugbank </a>link)</h4><ul><li>An antibacterial drug that is used against both gram-negative and gram-positive bacteria. Apparently used as an adjunct for the cytokine storm that occurs with COVID-19.</li></ul><h4>5. Favipiravir (or favilavir)</h4><ul><li>A rather obscure drug that was discovered in Japan and used for a variety of experimental applications. This is being explored as a treatment for COVID-19.</li></ul><p><a href="https://www.nature.com/articles/d41573-020-00016-0">Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</a></p><h4>6. Darunavir / Cobicistat</h4><ul><li>This is a drug used to treat HIV/AIDs as another antiretroviral. This is also an HIV protease inhibitor. Clinical trials are due to be published in late August / early September on effectiveness for treatment of SARS-CoV-2.</li></ul><h4>7. Linezolid (<a href="https://www.drugbank.ca/drugs/DB00601">drugbank </a>link)</h4><ul><li>An antibiotic used for multi-resistant bacteria.</li><li>This drug is being primarily used for a variety of gram positive bacterial infections. This would be used in conjunction with antivirals or other first line defenses in any case, but has been listed by Zhejiang University as an effective adjunct.</li></ul><h4>8. Voriconazole</h4><ul><li>Triazole antifungal used to treat serious <em>fungal </em>infections. It also affects the CYP450 enzymes of the liver. Can be useful for rare pulmonary fungal infections.</li><li>Likely a rather odd pharmacological treatment for COVID-19 but listed in several studies.</li><li><a href="https://link.springer.com/article/10.1007/s13730-019-00403-6"><em>Successful treatment</em></a><em> with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation</em></li></ul><h4>9. Efavirenz (<a href="https://www.drugbank.ca/drugs/DB00625">drugbank link</a>)</h4><ul><li>An HIV/AIDS antiretroviral drug that is often used in conjunction with other drugs such as tenofovir. Has potential for serious side effects, including everything from Stevens-Johnson syndrome, seizures to mild psychoactive / psychedelic effects.</li><li>Rather odd drug to use — but since supply is large in South Africa and other African countries it may be a last resort for such communities in the coming weeks.</li></ul><h4>10. Remdesivir (<a href="https://www.drugbank.ca/drugs/DB14761">drugbank link</a>)</h4><ul><li>Used as a treatment against ebola in 2016 and first used against coronaviruses such as SARS and MERS in <a href="https://www.ncbi.nlm.nih.gov/pubmed/28659436">2017</a>. However, these were almost entirely studies on mice and human trials are soon to be underway in 2020 by Gilead Sciences.</li><li>Said to block the RNA polymerase of Ebola and other viruses which stops replication in vitro and in vivo.</li><li>It was used with one of the first patients in the US who presented with COVID-19: <a href="https://www.nejm.org/doi/10.1056/NEJMoa2001191">https://www.nejm.org/doi/10.1056/NEJMoa2001191</a></li></ul><p><a href="https://stm.sciencemag.org/content/9/396/eaal3653?utm_campaign=toc_stm_2017-06-28&amp;et_rid=17050501&amp;et_cid=1410533">Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</a></p><h4>11. Ribavirin (<a href="https://www.drugbank.ca/drugs/DB00811">drugbank link</a>)</h4><ul><li>Used against a variety of broad spectrum DNA and RNA viruses, it interferes with the virus synthesis of mRNA which reduces or negates replication. Numerous other mechanisms of action that inhibit protein synthesis and replication of viral RNA.</li></ul><h4>12. Meropenem ( <a href="https://www.drugbank.ca/drugs/DB00760">drugbank link</a>)</h4><ul><li>Another antibiotic used in China alongside with corticosteroids such as methylprednisolone.</li><li>A Chinese study shows that it can cause substantive liver damage as seen below.</li></ul><p><a href="https://wwwnc.cdc.gov/eid/article/26/7/20-0445_article">Rhabdomyolysis as Potential Late Complication Associated with COVID-19</a></p><iframe src="https://drive.google.com/viewerng/viewer?url=https%3A//www.medrxiv.org/content/10.1101/2020.02.26.20026971v2.full.pdf&amp;embedded=true" width="600" height="780" frameborder="0" scrolling="no"><a href="https://medium.com/media/fcf9d2b7105e076e4cc30b388a1e6241/href">https://medium.com/media/fcf9d2b7105e076e4cc30b388a1e6241/href</a></iframe><h3>Concluding Remarks:</h3><p>There are a variety of pharmacological options for the treatment of the viral infection of COVID-19 and its various affects. I have mostly left out any usual pharmacological treatments that would be used for a more usual flu and/or pulmonary infection. Many of these would include normal antipyretics, corticosteroids, bronchodilators, etc… Nonetheless, antivirals and antiretrovirals are not conclusively effective against this disease. The primary complication of COVID-19 is pulmonary degradation and hypertension — which in turn end up negatively impacting all other organ systems, thereby leading to further negative health outcomes.</p><p><em>Other thoughts:</em></p><ul><li>See this Reddit Post on <a href="https://www.reddit.com/r/DrugNerds/comments/fru14e/covid19_antiviral_protocol/">COVID19 Antiviral Protocol</a> for some interesting list of naturally occurring compounds. I’m sure medicinal chemists have looked at these chemical structures already. Likely not a very interesting list in the reddit thread otherwise.</li></ul><p><em>Disclaimer: I do not have a background in virology, I have limited pharmacological knowledge of antivirals, antiretrovirals, and anti-microbials. My field of pharmacology primarily deals with neuropharmacology of affective disorders. Nonetheless, I hope this article provides some insight.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=93023f7324f9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Decreased directed functional connectivity in the psychedelic state]]></title>
            <link>https://pharmakeus.medium.com/decreased-directed-functional-connectivity-in-the-psychedelic-state-8941f48d6236?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/8941f48d6236</guid>
            <category><![CDATA[neuroscience]]></category>
            <category><![CDATA[lsd]]></category>
            <category><![CDATA[ketamine]]></category>
            <category><![CDATA[pharmacology]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Sun, 29 Dec 2019 12:03:39 GMT</pubDate>
            <atom:updated>2019-12-29T12:03:39.100Z</atom:updated>
            <content:encoded><![CDATA[<h3>Abstract</h3><p>Neuroimaging studies of the psychedelic state offer a unique window onto the neural basis of conscious perception and selfhood. Despite well understood pharmacological mechanisms of action, the large-scale changes in neural dynamics induced by psychedelic compounds remain poorly understood. Using source-localised, steady-state MEG recordings, we describe changes in functional connectivity following the controlled administration of LSD, psilocybin and low-dose ketamine, as well as, for comparison, the (non-psychedelic) anticonvulsant drug tiagabine. We compare both undirected and directed measures of functional connectivity between placebo and drug conditions. We observe a general decrease in directed functional connectivity for all three psychedelics, as measured by Granger causality, throughout the brain. These data support the view that the psychedelic state involves a breakdown in patterns of functional organisation or information flow in the brain. In the case of LSD, the decrease in directed functional connectivity is coupled with an increase in undirected functional connectivity, which we measure using correlation and coherence. This surprising opposite movement of directed and undirected measures is of more general interest for functional connectivity analyses, which we interpret using analytical modelling. Overall, our results uncover the neural dynamics of information flow in the psychedelic state, and highlight the importance of comparing multiple measures of functional connectivity when analysing time-resolved neuroimaging data.</p><h3><a href="https://www.sciencedirect.com/science/article/pii/S1053811919310535">https://www.sciencedirect.com/science/article/pii/S1053811919310535</a></h3><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8941f48d6236" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Involvement of medial prefrontal cortex NMDA and AMPA/kainate glutamate receptors in social…]]></title>
            <link>https://pharmakeus.medium.com/involvement-of-medial-prefrontal-cortex-nmda-and-ampa-kainate-glutamate-receptors-in-social-99b7a18a17d9?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/99b7a18a17d9</guid>
            <category><![CDATA[pharmacology]]></category>
            <category><![CDATA[neuroscience]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Sun, 29 Dec 2019 11:55:30 GMT</pubDate>
            <atom:updated>2019-12-29T11:55:30.936Z</atom:updated>
            <content:encoded><![CDATA[<h3>Involvement of medial prefrontal cortex NMDA and AMPA/kainate glutamate receptors in social recognition memory consolidation</h3><h3>Highlights</h3><p>•Social recognition memory (SRM) consolidation engages the mPFC.</p><p>•The blockade of NMDA receptors in the mPFC impaired SRM consolidation.</p><p>•The blockade of AMPA/kainate receptors in the mPFC impaired SRM consolidation.</p><h3>Abstract</h3><p>Social recognition memory (SRM) enables the distinction between familiar and strange conspecifics, a fundamental ability for sociable species, such as rodents and humans. There is mounting evidence that the medial prefrontal cortex plays a prominent role both in shaping social behavior and in recognition memory. Glutamate is the major excitatory neurotransmitter in the brain, and activity of its ionotropic receptors is known to mediate both synaptic plasticity and consolidation of various types of memories. However, whether these receptors are required in the medial prefrontal cortex (mPFC) for SRM consolidation remains elusive. To address this issue, we submitted rats to a social discrimination paradigm, administered infusions of NMDA- and AMPA/kainate-receptors antagonists into the prelimbic (PrL) subdivision of the mPFC at different post-encoding time points and evaluated long-term memory retention twenty-four hours later. We found that blocking NMDA receptors immediately after the sample phase, but not 3 h later, impaired SRM consolidation, whereas the blockade of AMPA/kainate receptors immediately and 3 h, but not 6 h after the sample phase, prevented long-term memory consolidation. These results highlight the importance of the mPFC in social cognition and may contribute towards the understanding of the dysfunctional social information processing that underlies multiple neuropsychiatric disorders.</p><p><a href="https://www.sciencedirect.com/science/article/pii/S1074742719302205">Involvement of medial prefrontal cortex NMDA and AMPA/kainate glutamate receptors in social recognition memory consolidation</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=99b7a18a17d9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Anxiety makes time pass quicker while fear has no effect]]></title>
            <link>https://pharmakeus.medium.com/anxiety-makes-time-pass-quicker-while-fear-has-no-effect-bc68eaedd6c0?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/bc68eaedd6c0</guid>
            <category><![CDATA[neuroscience]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[psychology]]></category>
            <category><![CDATA[anxiety]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Sun, 29 Dec 2019 11:50:05 GMT</pubDate>
            <atom:updated>2019-12-29T11:50:05.340Z</atom:updated>
            <content:encoded><![CDATA[<blockquote>Abstract</blockquote><blockquote>People often say that during unpleasant events, e.g. traumatic incidents such as car accidents, time slows down (i.e. time is overestimated). However aversive events can elicit at least two dissociable subtypes of reactions: fear (transient and relating to an imminent event) and anxiety (diffuse and relating to an unpredictable event). We hypothesised that anxiety might have an opposite effect on time perception compared to fear. To test this we combined a robust anxiety manipulation (threat-of-shock) with a widely used timing task in which participants judged whether the duration of a stimulus was long or short. In line with our hypothesis, across three experiments (with varying stimulus timings and shock levels), participants significantly underestimated time under inducted anxiety, as indicated by a rightward shift of the psychophysical function (meta-analytic effect size: d = 0.68, 95% confidence interval: 0.42–0.94). In two further studies, we were unable to replicate previous findings that fear leads to time overestimation, after adapting our temporal cognition task, which suggests a dissociation between fear and anxiety on how they affect time perception. Our results suggest that experimentally inducing anxiety leads to underestimating the duration of temporal intervals, which might be a starting point in explaining different subjective experiences of disorders related to fear (e.g. post-traumatic stress disorder) and anxiety (e.g. generalised anxiety disorder).</blockquote><p><a href="https://www.sciencedirect.com/science/article/abs/pii/S0010027719302902">Anxiety makes time pass quicker while fear has no effect</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bc68eaedd6c0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[MDMA-related deaths in Australia 2000 to 2018]]></title>
            <link>https://pharmakeus.medium.com/mdma-related-deaths-in-australia-2000-to-2018-c0a7cace0333?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/c0a7cace0333</guid>
            <category><![CDATA[pharmacology]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[neuroscience]]></category>
            <category><![CDATA[drugs]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Sun, 29 Dec 2019 11:42:02 GMT</pubDate>
            <atom:updated>2019-12-29T11:42:02.522Z</atom:updated>
            <content:encoded><![CDATA[<h3>Abstract</h3><h3>Background</h3><p>MDMA markets have undergone substantial changes internationally, with increasing manufacture of high purity MDMA recorded. This study examined trends in MDMA-related deaths in Australia, investigating characteristics, circumstances and toxicology of these deaths.</p><h3>Methods</h3><p>Analysis of MDMA-related deaths in Australia between 2001 and 2018, extracted from the National Coronial Information System (NCIS). Deaths were categorized into (1) drug toxicity deaths, where MDMA (with and without other drug) toxicity was considered by the coroner to be the underlying cause of death; and (2) other cause deaths, with MDMA (with and without other drug) intoxication/toxicity considered contributory to death.</p><h3>Results</h3><p>392 deaths were identified, with a median age of 26 years. 81% were male. Females were significantly younger than males (24 vs. 27 years). Two-thirds (62%) of deaths were attributed to drug toxicity (48% multiple drug toxicity and 14% MDMA toxicity alone), and one third (38%) to other causes (predominantly motor vehicle accidents) with MDMA recorded as a contributory factor. Death rates increased significantly between 2001 and 2007, declined between 2008 and 2010, and increased again between 2011 and 2016. Median MDMA concentration was 0.45 mg/L, and was significantly higher amongst females than males (0.70 vs. 0.42 mg/L). Deaths attributable to MDMA toxicity alone had a significantly higher blood MDMA concentration than multiple drug toxicity deaths (1.20 vs. 0.43 mg/L).</p><h3>Conclusions</h3><p>Deaths occurred predominantly among males in their mid-twenties, with females likely to be significantly younger. Three marked periods of trends in death rates (increases and declines) were observed, consistent with international supply trends. While most deaths were due to multiple drug toxicity, a notable proportion were attributed solely to MDMA toxicity.</p><h3><a href="https://www.sciencedirect.com/science/article/abs/pii/S0955395919303445">https://www.sciencedirect.com/science/article/abs/pii/S0955395919303445</a></h3><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c0a7cace0333" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional…]]></title>
            <link>https://pharmakeus.medium.com/preliminary-report-on-the-effects-of-a-low-dose-of-lsd-on-resting-state-amygdalar-functional-2b2bbebebdbb?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/2b2bbebebdbb</guid>
            <category><![CDATA[neuroscience]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Sun, 29 Dec 2019 11:41:10 GMT</pubDate>
            <atom:updated>2019-12-29T11:41:10.960Z</atom:updated>
            <content:encoded><![CDATA[<h3>Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional connectivity</h3><h3>Abstract</h3><p>The practice of “microdosing”, or the use of repeated, very low doses of LSD to improve mood or cognition, has received considerable public attention, but empirical studies are lacking. Controlled studies are needed to investigate both the therapeutic potential and the neurobiological underpinnings of this pharmacologic treatment. <em>Methods</em>. The present study was designed to examine the effects of a single low dose of LSD (13 micrograms) vs placebo on resting-state functional connectivity and cerebral blood flow in healthy young adults. Twenty men and women, aged 18–35, participated in two fMRI scanning sessions in which they received placebo or LSD under double-blind conditions. During each session, the participants completed drug effect and mood questionnaires, and physiological measures were recorded. During expected peak drug effect, they underwent resting-state BOLD and ASL scans. Cerebral blood flow as well as amygdala and thalamic connectivity were analyzed. <em>Results</em>. LSD increased amygdala seed-based connectivity with the right angular gyrus, right middle frontal gyrus, and the cerebellum, and decreased amygdala connectivity with the left and right postcentral gyrus and the superior temporal gyrus. This low dose of LSD had weak and variable effects on mood, but its effects on positive mood were positively correlated with the increase in amygdala — middle frontal gyrus connectivity strength. <em>Conclusions</em>. These preliminary findings show that a very low dose of LSD, which produces negligible subjective changes, alters brain connectivity in limbic circuits. Additional studies, especially with repeated dosing, will reveal whether these neural changes are related to the drug’s purported antidepressant effect. NCT03790358</p><p><a href="https://www.sciencedirect.com/science/article/abs/pii/S2451902219303477">Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional connectivity</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2b2bbebebdbb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A…]]></title>
            <link>https://pharmakeus.medium.com/pharmacological-interventions-targeting-anhedonia-in-patients-with-major-depressive-disorder-a-4294e0c1575a?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/4294e0c1575a</guid>
            <category><![CDATA[major-depressive-disorder]]></category>
            <category><![CDATA[depression]]></category>
            <category><![CDATA[psychiatry]]></category>
            <category><![CDATA[pharmacology]]></category>
            <category><![CDATA[anhedonia]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Wed, 09 Jan 2019 04:25:49 GMT</pubDate>
            <atom:updated>2019-01-09T04:25:49.878Z</atom:updated>
            <content:encoded><![CDATA[<h3>Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review</h3><h3>Abstract</h3><blockquote><a href="https://www.sciencedirect.com/topics/neuroscience/anhedonia">Anhedonia</a> is defined as a diminished ability to experience interest or pleasure, and is a critical psychopathological dimension of major depressive disorder (MDD). The purpose of the current systematic review is to evaluate the therapeutic efficacy of pharmacological treatments on measures of anhedonia in adults with MDD. Electronic databases Cochrane Library (CENTRAL), Ovid MEDLINE, PubMed, PsycINFO, and Google Scholar were searched from inception to June 1, 2018 for <a href="https://www.sciencedirect.com/topics/neuroscience/longitudinal-study">longitudinal studies</a> utilizing pharmacotherapy for the treatment of anhedonia in patients with MDD. A total of 17 eligible studies were identified (i.e., evaluated the effects of pharmacotherapy on a measure of anhedonia). Among the identified studies, the efficacy of 14 different pharmacotherapies on measures of anhedonia were evaluated, including melatonergic agents (i.e. agomelatine), monoaminergic agents (i.e. <a href="https://www.sciencedirect.com/topics/neuroscience/moclobemide">moclobemide</a>, <a href="https://www.sciencedirect.com/topics/neuroscience/clomipramine">clomipramine</a>, <a href="https://www.sciencedirect.com/topics/neuroscience/bupropion">bupropion</a>, <a href="https://www.sciencedirect.com/topics/neuroscience/venlafaxine">venlafaxine</a>, <a href="https://www.sciencedirect.com/topics/neuroscience/fluoxetine">fluoxetine</a>, amitifadine and <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/milnacipran">levomilnacipran</a>, <a href="https://www.sciencedirect.com/topics/neuroscience/escitalopram">escitalopram</a>, and sertraline), glutamatergic agents (i.e., <a href="https://www.sciencedirect.com/topics/neuroscience/ketamine">ketamine</a> and riluzole), stimulants (i.e., methylphenidate), and <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/psychotomimetic">psychedelics</a>(i.e., psilocybin). Based on the available evidence, most antidepressants demonstrated beneficial effects on measures of anhedonia as well as the other depressive symptoms. Only escitalopram/riluzole combination treatment was ineffective in treating symptoms of anhedonia in MDD. Continued research is warranted to further support the efficacy of mechanistically-distinct antidepressants in treating symptoms of anhedonia in MDD. Future research should also aim to parse out the heterogeneous effects of different pharmacotherapies on anhedonic symptoms.</blockquote><p><a href="https://www.sciencedirect.com/science/article/pii/S0278584618309175">Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4294e0c1575a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse]]></title>
            <link>https://pharmakeus.medium.com/the-prescription-opioid-crisis-role-of-the-anaesthesiologist-in-reducing-opioid-use-and-misuse-a2310a623e0b?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/a2310a623e0b</guid>
            <category><![CDATA[pharmacology]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[opioids]]></category>
            <category><![CDATA[neuroscience]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Wed, 09 Jan 2019 04:23:21 GMT</pubDate>
            <atom:updated>2019-01-09T04:23:21.318Z</atom:updated>
            <content:encoded><![CDATA[<h3>Abstract</h3><blockquote>Reports of strategies to prevent and treat the opioid epidemic are growing. Significant attention has been paid to the benefits of <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/opioid-dependence">opioid addiction</a> research, clinical prescribing, and public policy initiatives in curbing the epidemic. However, the role of the anaesthesiologist in minimising opioid use and misuse remains underexplored. For many patients with an opioid use disorder, the <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/perioperative-period">perioperative period</a> represents the source of initial exposure. As perioperative physicians, anaesthesiologists are in the unique position to manage pain effectively while simultaneously decreasing opioid consumption. Multiple opportunities exist for anaesthesiologists to minimise opioid exposure and prevent subsequent persistent opioid use. We present a global strategy for decreasing perioperative opioid use and misuse among surgical patients. A historical perspective of the opioid epidemic is presented, together with an analysis of opioid supply and demand forces. We then present specific temporal strategies for opioid use reduction in the perioperative period. We emphasise the importance of preoperative identification of patients at risk for long-term opioid use and misuse, review the evidence supporting the opioid sparing capacity of individual multimodal <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/anodyne">analgesic agents</a>, and discuss the benefits of <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/regional-anesthesia">regional anaesthesia</a> for minimising opioid consumption. We describe postoperative and post-discharge tools, including effective multimodal <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/analgesia">analgesia</a>and the role of a transitional pain service. Finally, we offer general institutional strategies that can be led by anaesthesiologists, identify gaps in knowledge, and offer directions for future research.</blockquote><p><a href="https://www.sciencedirect.com/science/article/pii/S0007091218313382">The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a2310a623e0b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity…]]></title>
            <link>https://pharmakeus.medium.com/withdrawal-of-caffeine-after-its-chronic-administration-modifies-the-antidepressant-like-activity-8dd0fffd2b6c?source=rss-f3ca80fee88c------2</link>
            <guid isPermaLink="false">https://medium.com/p/8dd0fffd2b6c</guid>
            <category><![CDATA[caffeine]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[depression]]></category>
            <category><![CDATA[pharmacology]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Pharmakeus]]></dc:creator>
            <pubDate>Wed, 10 Oct 2018 01:15:47 GMT</pubDate>
            <atom:updated>2018-10-10T01:15:47.747Z</atom:updated>
            <content:encoded><![CDATA[<h3>Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes</h3><h3>Abstract</h3><h3>Rationale</h3><p><em>Depressed patients often present increased consumption of caffeine.</em></p><h3>Objectives</h3><p><em>We aimed to investigate the effects of chronic treatment with caffeine (5 mg/kg, twice daily for 14 days) on the activity of single, ineffective doses of agomelatine (20 mg/kg) or mianserin (10 mg/kg) given on day 15 alone or simultaneously with caffeine.</em></p><h3>Methods</h3><p><em>We used the forced swim test (FST), tail suspension test (TST), and locomotor activity test in mice and quantitative real-time PCR analysis of the selected genes in the cerebral cortex (Cx).</em></p><h3>Results</h3><p><em>There were no changes in the immobility time between mice that received saline and caffeine for 14 days. Administration of agomelatine or mianserin on day 15 did not produce an antidepressant-like effect, but such effect was observed after administration of agomelatine or mianserin simultaneously with caffeine on day 15, in both mice that received saline and caffeine for 14 days. In mice treated with caffeine for 14 days, joint administration of agomelatine or mianserin and caffeine on day 15 decreased solute carrier family 6, member 15 (Slc6a15), messenger RNA (mRNA) level in the Cx, compared to the group which received only the respective antidepressant on this day. Moreover, in mice treated with caffeine for 14 days, joint administration of mianserin and caffeine on day 15 decreased adenosine A1 receptor (Adora1) and catechol-O-methyltransferase (Comt) mRNA level in the Cx, compared to the group which received mianserin without caffeine on this day.</em></p><h3>Conclusions</h3><p><em>Withdrawal of caffeine after its chronic intake can modify the activity of antidepressants. Adora1, Slc6a15, and Comt may be involved in the antidepressant-like effect observed after joint administration of caffeine and mianserin or agomelatine, following chronic treatment with caffeine.</em></p><p><a href="https://link.springer.com/article/10.1007/s00213-018-4940-6">Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8dd0fffd2b6c" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>